List of Excipients in Branded Drug PREVANTICS SWAB

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Professional Disposables International Inc	PREVANTICS SWAB	chlorhexidine gluconate and isopropyl alcohol	10819-1080	WATER	1969-12-31
Professional Disposables International Inc	PREVANTICS SWABSTICK	chlorhexidine gluconate and isopropyl alcohol	10819-4077	WATER	1969-12-31

Prevantics Swab Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Prevantics Swab is a hospital antiseptic product built around a high-concentration chlorhexidine gluconate (CHG) and isopropyl alcohol (IPA) formulation. Its commercial position depends less on conventional excipient innovation than on sterile packaging, rapid skin preparation, applicator design, supply reliability, and hospital purchasing contracts. Public labeling identifies CHG and IPA as active ingredients and purified water as the inactive ingredient. No publicly established composition-patent moat or standalone product revenue has been identified in the cited sources.

What is Prevantics Swab and what are its active ingredients?

Prevantics Swab is a single-use antiseptic applicator used for skin preparation before invasive procedures and other clinical interventions. Product labeling identifies:

Product characteristic	Publicly identified information
Product	Prevantics Swab / Prevantics antiseptic skin preparation
Primary active	Chlorhexidine gluconate, 3.15% weight/volume
Secondary active	Isopropyl alcohol, 70% volume/volume
Inactive ingredient	Purified water
Dosage form	Single-use impregnated swab or applicator
Primary setting	Hospitals, outpatient procedure centers and clinical care
Main use case	Preoperative and preprocedural skin antisepsis
Manufacturer	PDI Healthcare, associated with Nice-Pak Products
Product category	Topical antiseptic drug product with a delivery applicator

CHG provides persistent antimicrobial activity on the skin. IPA provides rapid microbial reduction and rapid evaporation. The formulation is therefore designed around complementary kinetics rather than around a large excipient system.

The product should be distinguished from CHG-only swabs, lower-strength CHG products, povidone-iodine preparations and alcohol-only products. Those products compete on drying time, skin tolerability, persistence, cost, staining, allergy considerations and procedure-specific purchasing protocols.

What excipients are used in Prevantics Swab?

The public product label identifies purified water as the inactive ingredient. CHG and IPA are active ingredients rather than excipients under the product’s labeling framework. The limited excipient profile has several commercial implications:

1. The formulation has a low inactive-ingredient burden.
2. There are fewer opportunities to differentiate through conventional formulation additives.
3. Container-closure compatibility and manufacturing controls become more important.
4. New commercial products would likely require reformulation, a new applicator, or a new use claim to create meaningful differentiation.

The formulation must maintain CHG stability, IPA concentration, microbial control and delivery uniformity throughout shelf life. The package must also limit IPA evaporation and prevent contamination after manufacture.

What excipient strategies could improve the product?

Potential formulation strategies include:

Strategy	Commercial purpose	Main technical or regulatory issue
Humectant addition	Reduce skin drying and irritation	May slow drying, alter CHG availability or affect residue
Mild emollient system	Improve tolerability during repeated use	Can reduce wetting, leave residue or interfere with adhesive dressings
Surfactant or wetting agent	Improve uniform skin coverage	Must be compatible with CHG and preserve antimicrobial performance
Buffering system	Control pH and improve stability	May affect skin tolerability and CHG activity
Low-residue solvent system	Improve drying and reduce tack	Requires validation of flammability and evaporation
Skin-conditioning polymer	Improve sensory profile	May impair antiseptic contact or create film-transfer issues
Reduced-alcohol variant	Address fragile-skin and pediatric segments	May reduce rapid kill performance and require new clinical evidence

The strongest near-term excipient opportunity is not simply adding more ingredients. It is developing a low-residue, skin-tolerable system that preserves fast drying and CHG persistence. Any additive must be tested against microbial efficacy, CHG release, drying time, flammability, skin irritation, sensitization and compatibility with surgical drapes, dressings, gloves and monitoring electrodes.

A more practical approach may be to maintain the core solution and innovate in the applicator. A controlled-volume applicator can improve dose consistency without changing the active formulation. This approach may reduce development risk compared with introducing a new inactive ingredient.

What formulations are protected by Prevantics Swab?

The commercial formulation is defined by its combination of high-strength CHG, 70% IPA and a single-use delivery format. The publicly available label does not establish a separate, publicly documented excipient patent portfolio for the product.

The likely protection layers are:

• Trademark rights covering the Prevantics brand.
• Regulatory exclusivity, if applicable to the approved drug application.
• Trade secrets covering manufacturing, filling, sterilization and packaging controls.
• Device or applicator intellectual property.
• Customer contracts and hospital formulary placement.
• Quality-system and supply-chain capabilities.
• Clinical or institutional preference for CHG-alcohol skin preparation.

A composition containing CHG and IPA is unlikely to create a durable patent barrier by itself unless the claims cover a narrow concentration range, a specific stability profile, a unique delivery system, a defined impurity profile or a clinically demonstrated performance advantage.

What is the FDA regulatory status of Prevantics Swab?

Prevantics is marketed as an FDA-regulated antiseptic product. FDA treatment of topical antiseptic products depends on the active ingredient, indication, concentration, dosage form and regulatory pathway. Healthcare antiseptics have faced a higher evidence burden than ordinary consumer antiseptic products, particularly for claims involving preoperative preparation and reduction of surgical-site infection risk.

Key regulatory issues include:

• Demonstration of antimicrobial effectiveness.
• Stability of CHG and IPA over the proposed shelf life.
• Control of IPA evaporation.
• Container-closure integrity.
• Flammability labeling and operating-room use.
• Skin irritation and sensitization.
• Applicator dose and coverage consistency.
• Compatibility with medical devices, adhesives and dressings.
• Manufacturing controls for a sterile or controlled-microbial product.

The drug solution and the applicator must be evaluated together when the applicator controls dose, exposure area or delivery performance. A reformulated product with a new excipient may require regulatory support beyond a simple packaging change.

What is the Orange Book status of Prevantics Swab?

The publicly cited product labeling does not establish a clear Orange Book patent listing or a public patent-expiration schedule for Prevantics Swab. A conventional generic-substitution pathway may also be less straightforward than for an oral tablet because the product combines a topical drug formulation with a single-use delivery system.

For a competing applicant, the relevant regulatory questions are:

1. Whether the product is approved under an NDA or another FDA pathway.
2. Whether the proposed copy can rely on the same active ingredients, concentrations and indications.
3. Whether the applicator is part of the approved product presentation.
4. Whether the applicant needs comparative performance data.
5. Whether any listed patents or exclusivity periods apply to the relevant application.

No verified patent number, expiration date or Paragraph IV litigation date should be attributed to Prevantics without a product-specific FDA and USPTO record.

When does Prevantics Swab lose exclusivity?

No verified public exclusivity expiration date is established by the cited product materials. Even if regulatory exclusivity has expired, commercial entry can remain difficult because the product is sold through hospital procurement systems and requires reliable delivery in a clinical workflow.

The practical loss-of-exclusivity timeline is therefore likely to depend on several events:

Event	Effect on competition
Expiration of regulatory exclusivity	Permits qualifying applications to proceed
Expiration of enforceable formulation or applicator patents	Removes a legal barrier
Availability of an equivalent delivery format	Reduces substitution friction
Hospital acceptance of a competing product	Creates purchasing access
Completion of comparative efficacy and safety work	Supports regulatory approval
Reliable manufacturing and supply	Enables sustained commercial launch

A competitor can enter after formal legal exclusivity ends but still fail to gain market share if it cannot match applicator performance, packaging, product availability and contract pricing.

What generic entry risks exist for Prevantics Swab?

Generic and branded-generic risk is moderate rather than binary. The active ingredients are established antiseptics, which reduces scientific novelty. The barriers are primarily product equivalence, regulatory evidence and procurement execution.

High-risk entry scenarios

• A competitor launches a closely matched 3.15% CHG/70% IPA product.
• A lower-cost applicator offers equivalent skin coverage and drying time.
• A hospital group standardizes on a competing CHG-alcohol product.
• A manufacturer secures a private-label contract with a major distributor.
• Supply disruption creates an opening for an approved alternative.

Lower-risk entry scenarios

• The competitor changes the excipient system and must generate new compatibility data.
• The applicator has inconsistent wetting or drying.
• The product lacks evidence for the intended procedure.
• Packaging increases waste or complicates sterile-field handling.
• The competitor cannot meet hospital volume and delivery requirements.

Paragraph IV litigation risk cannot be quantified from the cited public materials because no confirmed Orange Book-listed patent position is established here. If the product is protected primarily by trade secrets, device claims or commercial contracts, litigation may focus on unfair competition, patent infringement outside the Orange Book system, regulatory misrepresentation or contract disputes rather than a standard Paragraph IV case.

How strong is the patent estate for Prevantics Swab?

The public record described by the product label indicates a potentially limited composition-patent moat. The stronger barriers are likely operational:

• Specialized filling of volatile IPA-containing solutions.
• Control of CHG concentration and uniform impregnation.
• Applicator and package engineering.
• Flammability and transport compliance.
• Validated shelf-life performance.
• Hospital supply contracts.
• Formulary and infection-control acceptance.

A strong patent estate would require claims covering a narrow formulation, a specific applicator architecture, a stability solution, or a measurable clinical advantage. Without verified patent numbers and claim scope, the product should not be valued as a heavily patent-protected pharmaceutical franchise.

What commercial opportunities exist for Prevantics Swab?

The largest opportunities are line extensions and channel expansion rather than a wholesale change to the core formulation.

Hospital and procedure-center expansion

Potential targets include:

• Operating-room skin preparation.
• Central venous catheter insertion.
• Peripheral intravenous catheter placement.
• Interventional radiology.
• Cardiac catheterization.
• Dialysis access procedures.
• Emergency departments.
• Ambulatory surgery centers.
• Dental and oral-surgical procedures where appropriate.
• Home-infusion and specialty nursing channels.

Institutional buyers value standardization. A product that reduces preparation steps, improves coverage consistency and lowers infection-control variation can support premium pricing.

Pediatric and fragile-skin products

A lower-irritation version could address neonates, pediatrics, geriatric patients and patients requiring repeated preparation. The central challenge is preserving antimicrobial performance while reducing alcohol-related discomfort and skin dryness.

Possible approaches include:

• Smaller dose formats.
• Lower-volume applicators.
• Improved mechanical coverage with less solution.
• A controlled-release or reduced-residue delivery system.
• A separate lower-alcohol formulation supported by clinical evidence.

These products should be treated as distinct regulatory and clinical programs, not simple label extensions.

Applicator and packaging innovation

The strongest near-term product-development opportunities include:

• Ergonomic handles for one-handed use.
• Audible activation or breakage confirmation.
• Dose indicators.
• Reduced package size.
• Peel-open packaging for sterile-field access.
• Applicators sized for pediatric, vascular-access and surgical fields.
• Packaging that limits IPA loss after opening.
• Lower-plastic or recyclable components that meet sterile packaging requirements.

A new applicator can create differentiation while preserving the established active ingredients. It may also support device patents and reduce direct price comparison.

How does Prevantics compare with competing antiseptic products?

Product category	Strength	Limitation	Competitive position
CHG plus IPA	Rapid and persistent antimicrobial activity	Skin irritation, flammability and CHG sensitivity concerns	Direct competitive category
Povidone-iodine	Broad familiarity and established use	Less persistent activity and staining concerns	Alternative where CHG is unsuitable
IPA-only	Fast drying and low formulation complexity	Limited persistence	Lower-cost alternative
CHG-only	Persistence without the same alcohol load	Slower initial action	Relevant for sensitive-skin segments
Alcohol plus other antiseptic	May offer different tolerability or spectrum	Less established procurement preference	Potential challenger category

Prevantics is most exposed to products that combine comparable CHG concentration, 70% IPA, convenient packaging and lower acquisition cost. It is less exposed where hospitals prioritize iodine, reduced alcohol exposure or a specific applicator format.

What litigation and licensing issues affect Prevantics Swab?

No confirmed Prevantics-specific patent litigation or settlement agreement is identified in the cited sources. No publicly disclosed licensing transaction has been tied directly to the Prevantics formulation in the cited materials.

Commercial diligence should focus on:

• Ownership of the Prevantics trademark.
• Ownership of formulation and applicator patents.
• Manufacturing agreements.
• Distribution and private-label arrangements.
• Hospital group purchasing contracts.
• Exclusivity provisions with applicator or packaging suppliers.
• Any change-of-control restrictions.
• Patent rights covering competing CHG-alcohol formulations.

Because PDI is associated with Nice-Pak, manufacturing and distribution relationships may be strategically important even where the formulation itself is not strongly patent-protected.

What is the revenue exposure and market opportunity?

Standalone Prevantics revenue is not publicly reported in the cited materials. Exposure should be assessed through procedure volume, hospital contract penetration, average units per procedure and pricing relative to competing antiseptic products.

The most attractive commercial segments are those in which:

• Skin preparation is mandatory.
• Product selection is standardized.
• Infection-control protocols favor CHG-alcohol products.
• The applicator saves staff time.
• Supply reliability has high value.
• Hospitals purchase through recurring contracts.

The main downside risks are hospital price compression, product commoditization, CHG safety concerns, procurement consolidation and substitution by lower-cost alternatives.

Key Takeaways

• Prevantics Swab uses 3.15% CHG and 70% IPA; purified water is identified as the inactive ingredient.
• The formulation has limited conventional excipient differentiation.
• The strongest innovation opportunities are applicator design, packaging, skin tolerability and procedure-specific formats.
• No verified public patent-expiration date, Orange Book listing, Paragraph IV case or settlement agreement is established in the cited product materials.
• The product’s commercial moat is likely based on regulatory compliance, manufacturing control, hospital contracts and workflow integration.
• Generic entry risk is meaningful because CHG and IPA are established actives, but equivalent applicator performance and hospital procurement access remain significant barriers.
• Pediatric, fragile-skin, ambulatory-surgery and vascular-access formats offer the clearest line-extension opportunities.

FAQs About Prevantics Swab

Is Prevantics Swab a drug or a medical device?

It is a topical antiseptic drug product delivered through a single-use swab or applicator. The drug solution and delivery presentation must be assessed together for regulatory and commercial equivalence.

Does Prevantics Swab contain an excipient other than water?

Public labeling identifies purified water as the inactive ingredient. CHG and IPA are listed as active ingredients.

Can a competitor copy the Prevantics formulation?

A competitor may be able to develop a product with the same active ingredients and concentrations, but it must address regulatory requirements, product performance, packaging, flammability, stability and hospital procurement acceptance.

Is Prevantics Swab suitable for pediatric patients?

A CHG-alcohol product may have age, skin-condition and procedural limitations. Pediatric use depends on the applicable product labeling and institutional protocol.

What is the best licensing opportunity around Prevantics Swab?

The most commercially credible opportunities are applicator technology, controlled-dose delivery, packaging systems, skin-tolerability formulations and private-label distribution rather than licensing a novel active pharmaceutical ingredient.

References

1. DailyMed. (n.d.). Prevantics antiseptic skin solution product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). FDA drug databases and Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases

3. U.S. Food and Drug Administration. (2017). Safety and effectiveness of health care antiseptics; topical antimicrobial drug products for over-the-counter human use. Federal Register, 82 Fed. Reg. 60474.

4. Centers for Disease Control and Prevention. (2011). Guidelines for the prevention of intravascular catheter-related infections. https://www.cdc.gov/infection-control/

5. PDI Healthcare. (n.d.). Prevantics antiseptic products. https://pdihc.com/